Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (261-270 of 305) with videos related to

Pageof 31
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2018
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCA Lisberg, A Cummings, J W Goldman, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
The Lancet. Oncology|December 7, 2020
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialJonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Cancer Immunology Research|February 1, 2018
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single CenterAaron Lisberg, D Andrew Tucker, Jonathan W Goldman, et al.
Pageof 31

Showing results (261-270 of 305) with videos related to

Sort By:
Pageof 31
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2018
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCA Lisberg, A Cummings, J W Goldman, et al.
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
The Lancet. Oncology|December 7, 2020
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialJonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
Cancer Immunology Research|February 1, 2018
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single CenterAaron Lisberg, D Andrew Tucker, Jonathan W Goldman, et al.
Pageof 31